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Both acute and chronic pancreatitis are frequent diseases of the pancreas, which, despite 51 
being of benign nature, are related to a significant risk of malnutrition and may require 52 
nutritional support. Acute necrotizing pancreatitis is encountered in 20% of patients 53 
with acute pancreatitis, is associated with increased morbidity and mortality, and may 54 
require artificial nutrition by enteral or parenteral route, as well as additional 55 
endoscopic, radiological or surgical interventions. Chronic pancreatitis represents a 56 
chronic inflammation of the pancreatic gland with development of fibrosis. Abdominal 57 
pain leading to decreased oral intake, as well as exocrine and endocrine failure are 58 
frequent complications of the disease. All of the above represent risk factors related to 59 
malnutrition. Therefore, patients with chronic pancreatitis should be considered at risk, 60 
screened and supplemented accordingly. Moreover, osteoporosis and increased facture 61 
risk should be acknowledged in patients with chronic pancreatitis, and preventive 62 
measures should be considered. 63 
  64 
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1. Introduction 65 
Acute pancreatitis (AP) is the most common acute gastrointestinal disease requiring 66 
hospital admission (1), with the outcome being favorable in most cases (80%) (2). 67 
However, acute necrotizing pancreatitis (ANP) may develop in up to 20% of patients and 68 
is associated with significant rates of early organ failure (38%), need for intervention 69 
(38%), and death (15%) (2). Catabolism is very high in this setting; therefore, 70 
nutritional support is one of the cornerstones of management (3). A significant amount 71 
of research has shown the superiority of enteral over parenteral nutrition in ANP, 72 
creating a paradigm shift a decade ago and modifying the management strategy (3). 73 
Nevertheless, additional questions regarding the timing, route and type of enteral 74 
nutrition (EN), as well as the place of oral refeeding, are still the objects of clinical 75 
investigations.  76 
Chronic pancreatitis (CP) is a disease in which recurrent inflammatory episodes lead to 77 
replacement of the pancreatic parenchyma by fibrous connective tissue (4). The major 78 
consequence of CP is the loss of functional exocrine and endocrine pancreatic tissue, 79 
thus resulting in both exocrine and endocrine insufficiency (4). Pain is also frequently 80 
encountered in patients with CP, and seems to be related to a multitude of factors such 81 
as pancreatic neural remodeling and neuropathy, increased intraductal and 82 
parenchymal pressure, pancreatic ischemia and acute inflammation during an acute 83 
relapse (5). Both pain and loss of pancreatic function can lead to malnutrition in patients 84 
with CP (4). Moreover, other long-term consequences such as osteoporosis are 85 
frequently overlooked, despite their potential impact on quality of life in patients with 86 
CP. Therefore, screening for malnutrition and nutritional support play a crucial part in 87 
the multimodal management required in this setting. 88 
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Although recent guidelines for AP (2) and CP (4) have been published, a dedicated 89 
consensus on nutritional support in pancreatic diseases is lacking.  90 
2. Methods 91 
The present guideline was developed according to the standard operating procedure for 92 
ESPEN guidelines (6). The guideline was developed by an expert group of 13 authors 93 
from eleven European countries.  94 
Methodology of guideline development 95 
Based on the standard operating procedures for ESPEN guidelines and consensus 96 
papers, the first step of the guideline development was the formulation of so-called PICO 97 
questions which address specific patient groups or problems, interventions, compare 98 
different therapies and are outcome-related (6). In total, 31 PICO questions were 99 
created and split into two main chapters, “Acute pancreatitis” and “Chronic 100 
Pancreatitis”. To answer these PICO questions, a literature search was performed to 101 
identify suitable meta-analyses, systematic reviews and primary studies, published from 102 
1977 up to December 2018. The PICO questions were allocated to subgroups/experts 103 
for the different subjects who created 42 recommendations and seven statements. For 104 
grading the literature, the grading system of the Scottish Intercollegiate Guidelines 105 
Network (SIGN) was used (7). Allocation of studies to the different levels of evidence is 106 
shown in Table 1. Supportive of the recommendations, the working group added 107 
commentaries to the recommendations where the bases of the recommendations are 108 
explained. 109 
The recommendations were graded according to the levels of evidence assigned (Table 110 
2). The wording of the recommendations reflect the grades of recommendations, level A 111 
is indicated by “shall”, level B by “should” and level 0 by “can/may”. The good practice 112 
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point (GPP) is based on experts’ opinions due to the lack of studies, here, the wording 113 
can be chosen deliberately.  114 
Online voting on the recommendations was performed on the guideline-services.com 115 
platform. All ESPEN members were invited to agree or disagree with the 116 
recommendations and to comment on them. A first draft of the guideline was also made 117 
available to the participants; on that occasion 36 recommendations and all seven 118 
statements reached an agreement of >90%, six recommendations reached an agreement 119 
of 75-90% and no recommendation an agreement of <75%. Those recommendations 120 
with an agreement of >90%, which means a strong consensus (Table 3) were passed 121 
directly; all others were revised according to the comments and voted on again during a 122 
consensus conference, which took place on 29th April 2019. All recommendations 123 
received an agreement of >90%. During the consensus conference, one of the original 124 
recommendations was considered redundant and one statement was transformed into a 125 
recommendation. Therefore, the guideline comprises 42 recommendations and six 126 
statements. To support the recommendations and the assigned grades of 127 
recommendation, the ESPEN guideline office created evidence tables of relevant meta-128 
analyses, systematic reviews and randomized controlled trials (RCTs). These evidence 129 
tables are available online as supplemental material to this guideline. 130 
Search strategy 131 
A comprehensive literature research including systematic reviews, controlled clinical 132 
trials and cohort studies, with the keywords and filters presented in Table 4 was 133 
performed. We initially searched Pubmed, Cochrane Library and EMBASE for recent, 134 
rigorous systematic reviews and meta-analyses that answered our clinical questions. In 135 
the absence of these, we looked for comparative studies, whether randomized or not. 136 
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The search phrases included the following terms: (acute pancreatitis OR acute 137 
necrotizing pancreatitis OR chronic pancreatitis OR pancreatitis OR 138 
hypertriglyceridemic pancreatitis OR hyperlipidemic pancreatitis) AND (nutritional 139 
status OR nutritional assessment OR nutritional screening OR malnutrition OR oral 140 
feeding OR enteral nutrition OR tube feeding OR parenteral nutrition OR intravenous 141 
nutrition OR timing OR formula OR formulation OR nasogastric tube OR nasojejunal tube 142 
OR digestive intolerance OR necrosectomy OR minimally invasive OR increased intra-143 
abdominal pressure OR abdominal compartment syndrome OR open abdomen OR 144 
immunonutrition OR glutamine OR antioxidants OR probiotics OR enzyme 145 
supplementation OR enzyme replacement therapy OR micronutrients OR 146 
macronutrients OR nutrient deficiency OR diet OR fat OR nitrogen OR dietary protein OR 147 
carbohydrates oral supplementation OR medium chained triglycerides OR osteoporosis 148 
OR osteopenia). 149 
Finally, 88 articles were selected for the AP chapter, and 111 articles for the CP chapter.  150 
 151 
  152 
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3. Results 153 
I. Acute pancreatitis 154 
1. Which patients with AP are considered at nutritional risk? 155 
Statement 1 156 
Patients with AP should be considered at moderate to high nutritional risk, 157 
because of the catabolic nature of the disease and because of the impact of the 158 
nutritional status for disease development. 159 
Strong consensus (97% agreement) 160 
 161 
Recommendation 1 162 
All patients with predicted mild to moderate AP should be screened using 163 
validated screening methods such as the Nutritional Risk Screening – 2002 (NRS-164 
2002); however, the patients with predicted severe AP should always be 165 
considered at nutritional risk. 166 
Grade of Recommendation B – Strong consensus (100% agreement) 167 
 168 
Commentary 169 
Fortunately, the majority of patients with AP have predicted mild or moderately severe 170 
forms of the disease that are self-limited with fully recovery in less than a week, in 171 
whom oral feeding can be started within few days after the onset of AP (9). Gut-barrier 172 
dysfunction may occur in up to 60% of patients with AP; mostly in severe AP and it is 173 
thought to lead to bacterial translocation and infection of necrosis (10). Along with the 174 
increased catabolic state related to the disease, patients with predicted severe AP are 175 
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considered at nutritional risk (11). Nevertheless, malnourished patients should also be 176 
considered at nutritional risk, even if they have predicted mild AP, because of their pre-177 
existing condition. Similarly, patients with increased alcohol consumption are frequently 178 
malnourished (12). Scoring systems such as the NRS 2002 (13), can be helpful in 179 
identifying these patients (14-17). These scores have been validated in hospitalized, as 180 
well as critically ill patients. Nevertheless, no studies have validated these scoring 181 
systems in a specific population of patients with AP (18). 182 
A low body mass index (BMI) may also identify patients who are at nutritional risk. 183 
Nevertheless, obesity is a known risk factor for severe AP and is, therefore, a disease 184 
severity-related nutritional risk (19). 185 
 186 
2. Is early oral feeding feasible in patients with predicted mild AP? 187 
Recommendation 2 188 
Oral feeding shall be offered as soon as clinically tolerated and independent of 189 
serum lipase concentrations in patients with predicted mild AP. 190 
Grade of Recommendation A – Strong consensus (100% agreement) 191 
 192 
Recommendation 3 193 
Low-fat, soft oral diet shall be used when reinitiating oral feeding in patients with 194 
mild AP. 195 





Most patients with AP suffer from disease of a mild to moderate severity, non-199 
necrotizing type with an uncomplicated clinical course. Four RCTs have shown that 200 
patients with mild to moderate AP can tolerate early oral feeding and this strategy is 201 
related with a shorter length of stay compared with conventional oral feeding 202 
(introduced after enzyme decrease, pain resolution and bowel movement) (9, 20-23). 203 
Furthermore, one of these trials revealed that oral food intake is safe and well-tolerated 204 
independently of the course and normalization of serum lipase (20). Immediate oral 205 
feeding with a soft diet seems to be more beneficial regarding caloric intake and equally 206 
tolerated compared with clear liquid diets (23-25). A meta-analysis confirmed that early 207 
oral feeding was feasible in patients with predicted mild AP and reduced length of stay 208 
(26). A recent meta-analysis including 17 studies identified that 16.3% of patients with 209 
AP will subsequently have intolerance to oral feeding (27). Predictive factors included 210 
the presence of pleural effusions and/or collections and severity (higher 211 
Ranson/Glasgow and Balthazar scores). 212 
Hyperlipidemia is the third most common cause of AP and accounts for 4-10% of cases 213 
(28). It was reported that hyperlipidemia is associated with a worse prognosis of AP 214 
than other etiological factors (28-30). The initial management of hyperlipidemic AP is 215 
the same as for all other causes of the disease, but subsequent management in addition 216 
to generalized supportive measures may include etiology-specific targeted therapies. 217 
These include initially putting patients on a nil by mouth regimen for 24-48 hours, 218 
subsequent dietary modifications, medical management with the different classes of 219 
anti-hyperlipidemic agents, in-hospital pharmacological treatment with insulin and/or 220 
heparin and plasmapheresis. Whilst these measures are effective in lowering 221 
triglyceride concentrations, they do not appear to affect the outcome of AP (28, 29). 222 
However, tight regulation of triglyceride concentration after presentation with AP was 223 
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found to reduce the risk of recurrence. These include a low fat diet, encouragement of 224 
weight loss and treatment with a fibrate, with the addition of a statin if 225 
hypercholesterolemia is present in addition to hypertriglyceridemia (28). 226 
 227 
3. If required, what type of medical nutrition (enteral or parenteral) is preferable in 228 
patients with AP? 229 
Recommendation 4 230 
In patients with AP and inability to feed orally, EN shall be preferred to parenteral 231 
nutrition (PN). 232 
Grade of Recommendation A – Strong consensus (97% agreement) 233 
 234 
Commentary 235 
EN is supposed to preserve the integrity of the gut mucosa, stimulate intestinal motility, 236 
prevent bacterial overgrowth, and increase the splanchnic blood flow (10). Currently 237 
there are twelve RCTs and eleven systematic reviews/meta-analyses including a 238 
Cochrane-standard meta-analysis which clearly prove that in patients with severe AP, 239 
EN is safe and well-tolerated, with significant decreases in complication rates, multi-240 
organ failure, and mortality, compared with PN (31-41). The meta-analysis by Al-Omran 241 
et al. was performed to Cochrane-standards on the basis of eight RCTs with 348 patients 242 
and clearly shows that early EN when compared with initial total PN, significantly 243 
decreases mortality by 50% (OR 0.50 [95% CI 0.28 to 0.91]), rate of infection (OR 0.39 244 
[95% CI 0.23 to 0.65]), multi-organ failure (0.55 [95% CI 0.37 to 0.81]) as well as the 245 
necessity for operation (OR 0.44 [95% CI 0.29 to 0.67]) (35). Furthermore if only 246 
patients with severe AP were included in this meta-analysis, mortality further decreased 247 
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by more than 80% [0.18 [95 % CI 0.006 to 0.58]) (35). These results were confirmed by 248 
more recent meta-analyses, including a latest publication including only critically ill 249 
patients with AP (39). Compared with PN, EN was associated with a significant 250 
reduction in overall mortality (RR 0.36, 95% CI 0.20 to 0.65, p=0.001) and the rate of 251 
multiple organ failure (RR 0.39, 95% CI 0.21 to 0.73, p=0.003). 252 
 253 
4. What is the optimal timing for initiating EN in patients with AP? 254 
Recommendation 5 255 
EN should be started early, within 24-72 hours of admission, in case of intolerance 256 
to oral feeding 257 
Grade of Recommendation B – Strong consensus (92% agreement) 258 
 259 
Commentary 260 
Several meta-analyses have investigated the clinical effects and tolerance of early EN in 261 
patients with AP either within 24 hours (42-44) or 48 hours (45-47) of admission. All 262 
these meta-analyses clearly reveal that early EN is feasible, safe and well-tolerated and 263 
associated with substantial clinical benefits regarding mortality, organ failure and 264 
infectious complications for both time-points compared with delayed EN. Nevertheless, 265 
a potential bias could be that five of these meta-analysis included studies which had 266 
patients receiving PN in their control groups (42-46). One meta-analysis, compared 267 
early (within 24 hours) with late enteral nutrition (after 72 hours), but no comparison 268 
was made between 24 and 48 hours (44). 269 
In contrast to these data from the aforementioned meta-analyses that provided strong 270 
evidence for early EN within 24-48 hours, a multicenter RCT (208 patients with 271 
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predicted severe AP) found no difference in the rate of major infection or death between 272 
early EN, started within 24 hours after admission, and an oral diet initiated 72 hours 273 
after admission (48). A second RCT (214 patients with AP) confirmed these results, 274 
showing no significant reduction in persistent organ failure and mortality in patients 275 
receiving early EN compared with patients receiving no nutritional support (49). A 276 
plausible explanation could be that these trials included mostly patients with mild or 277 
moderate AP (in the Bakker trial there were only 63% of cases with necrotizing AP 278 
(48)); therefore, the beneficial effect of early EN could be less pronounced.  279 
Finally, a prospective cohort study including 105 patients with AP concluded that the 280 
third day after hospital admission was the best cut-off time for early EN (with an area 281 
under the curve of 0.744), by reducing the risk of secondary infection and improving the 282 
nutritional status of patients, with a better tolerance (50). 283 
 284 
5. What type of EN is indicated? 285 
Recommendation 6 286 
In patients with AP a standard polymeric diet shall be used. 287 
Grade of Recommendation A – Strong consensus (97% agreement) 288 
 289 
Commentary 290 
Most studies that evaluated the clinical benefits of early EN in comparison with total PN 291 
used semi-elemental formulae while the recent studies were performed with polymeric 292 
formulae. In all studies both types of formulae were proven to be feasible, safe and well-293 
tolerated. One small RCT in 30 patients found that both formulae were safe and well-294 
tolerated (based on a visual analogue scale and number of stools per day) with some 295 
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clinical benefits for semielemental diets, including length of stay (23 ± 2 vs. 27 ± 1 days, 296 
p = 0.006) and weight maintenance (51). On the other hand an indirect adjusted meta-297 
analysis of Petrov et al. on 428 patients using PN as a reference treatment showed no 298 
differences regarding tolerance, rate of infection and mortality between both formulae 299 
(52). Finally, a second, more recent meta-analysis, including 15 trials (1376 300 
participants), showed no evidence to support a specific enteral formula (53). 301 
Nevertheless, a subgroup of patients with severe AP may have malabsorption and 302 
therefore, semi-elemental diets could be of interest. 303 
 304 
6. What route should be used for EN in patients with AP? 305 
Recommendation 7 306 
If EN is required in patients with AP, it should be administered via a nasogastric 307 
tube. Administration via a nasojejunal tube should be preferred in case of 308 
digestive intolerance. 309 
Grade of Recommendation B – Strong consensus (95% agreement) 310 
 311 
Commentary 312 
Three RCTs compared nasojejunal with nasogastric support route in patients with 313 
severe AP (54-56) showed no differences regarding tolerance, complications rates and 314 
mortality. Four meta-analyses (57-60) conclude that nasogastric tube feeding is feasible, 315 
safe and well-tolerated and, compared with nasojejunal tube feeding, does not increase 316 
complication rate, mortality, refeeding pain recurrence or prolong hospital stay in 317 
patients with severe AP. Compared with nasojejunal tubes, nasogastric tubes are much 318 
easier to place, more convenient and cheaper. Nevertheless, about 15% of patients will 319 
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experience digestive intolerance, mostly because of delayed gastric emptying and gastric 320 
outlet syndrome (57, 58) and in this situation, nasojejunal tube feeding is required. 321 
Furthermore, potential bias arises from the small number of patients included in the 322 
aforementioned trials and the use of different criteria to define severe AP. 323 
 324 
7. In patients with AP, when should PN be initiated? 325 
Recommendation 8 326 
PN should be administered in patients with AP who do not tolerate EN or who are 327 
unable to tolerate targeted nutritional requirements, or if contraindications for 328 
EN exist. 329 
Grade of Recommendation GPP – Strong consensus (97% agreement) 330 
 331 
Commentary 332 
The primary nutritional route in all patients with severe AP should be enteral, as this 333 
route has been shown to have benefits over other regimens. However, PN is indicated in 334 
patients with severe AP who do not tolerate EN or who are unable to tolerate targeted 335 
requirements, or if there exists contraindication for EN overall. Complications of severe 336 
AP, which may occur and represent a contraindication for EN, include bowel obstruction, 337 
abdominal compartment syndrome, prolonged paralytic ileus and mesenteric ischemia 338 
(61). Similar to critically ill patients with other diseases, approximately 20% of patients 339 
with severe AP have complications, which are associated with absolute or relative 340 




8. How should medical nutrition be provided in case of necrosectomy (endoscopically or by 343 
minimally invasive surgery) in patients with severe AP? 344 
Recommendation 9 345 
Oral food intake in patients undergoing minimally invasive necrosectomy is safe 346 
and feasible and should be initiated in the first 24 hours after the procedure, if the 347 
clinical state (hemodynamic stability, septic parameters, gastric emptying) of the 348 
patient allows it.  349 
Grade of Recommendation GPP – Strong consensus (95% agreement) 350 
 351 
Recommendation 10 352 
In patients undergoing minimally invasive necrosectomy who are unable to be fed 353 
orally, EN is indicated via nasojejunal as preferred route.  354 
Grade of Recommendation B – Strong consensus (91% agreement) 355 
 356 
Recommendation 11 357 
PN is indicated in patients undergoing minimally invasive necrosectomy who do 358 
not tolerate EN or who are unable to tolerate targeted nutritional requirements, 359 
or if there exist contraindications for EN.  360 





Approximately 10-20% of patients with AP will develop necrosis of the pancreas and/or 364 
peripancreatic tissue (ANP) (1, 2). These patients with ANP have moderate or severe 365 
forms of AP, and a higher risk for development of multiple organ failure, secondary 366 
infection of the necrosis, and death (62). After proven benefits of the “step-up” 367 
(minimally invasive approach) over the open approach for the treatment of ANP (63), 368 
minimally invasive techniques have been used extensively (64). Furthermore, the Dutch 369 
Pancreatitis Study Group recently showed a lower rate of pancreatic fistula and better 370 
cost benefits of endoscopic over surgical step-up approach for infected necrotizing 371 
pancreatitis (65). Unfortunately, to date there are no published data on nutritional 372 
support in patients with AP treated by the minimally invasive approach. In the 373 
aforementioned trial (65), all patients received oral nutrition, if tolerated. If this was not 374 
tolerated, a nasojejunal feeding tube was introduced and EN was started. If 375 
gastrointestinal feeding was contraindicated, the patient received PN. No specific data 376 
were reported regarding nutrition-related outcomes.  377 
In the RCT by Bakker et al. (48), there was no superiority of early (first 24 hours) 378 
nasojejunal tube feeding when compared with an oral diet after 72 hours in reducing the 379 
rate of infection or death in patients with predicted severe AP. In this trial interventional 380 
procedures due to necrotizing pancreatitis included percutaneous catheter drainage, 381 
endoscopic transgastric drainage or necrosectomy and surgical necrosectomy (without 382 
information on the type of surgery performed – minimally invasive or open approach). 383 
The authors did not find any difference in the number of patients who underwent 384 
interventions between groups (24 percutaneous drainages in early EN group vs. 46 in 385 
the on demand feeding group, p = 0.13; eight endoscopic transgastric drainage or 386 
necrosectomy in the early EN group vs. six in the on-demand feeding group, p = 0.53; 387 
and three surgical necrosectomy in the early EN group vs. seven in the on-demand 388 
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feeding group, p = 0.49). In this trial PN was not used, as it was not mentioned in the 389 
feeding protocol of the study. In a retrospective series of 37 patients undergoing 390 
laparoscopic transgastric necrosectomy, an oral food intake 24-48 hours after the 391 
procedure was feasible and safe (66). In one prospective study on video-assisted 392 
retroperitoneal debridement (VARD) the feeding regimen was reported but without 393 
specified time of initiation and reasons for shifting oral nutrition to EN or PN (67). Forty 394 
patients in that study were fed by nasojejunal tube as the preferred route when 395 
tolerated; otherwise, PN was given (67). Therefore, based on small series, nasojejunal 396 
feeding seems safe in patients having undergone minimally invasive necrosectomy. 397 
Nevertheless, definitive data are missing. 398 
 399 
9. How should medical nutrition (EN and PN) be provided in critically patients with severe 400 
AP (intra-abdominal hypertension (IAH), abdominal compartment syndrome (ACS) with 401 
need for open abdomen)? 402 
 403 
Recommendation 12 404 
In patients with severe AP and intraabdominal pressure (IAP) < 15 mmHg early 405 
EN shall be initiated via nasojejunal, as the preferred route, or nasogastric tube. 406 
IAP and the clinical condition of patients during EN shall be monitored 407 
continuously. 408 




Recommendation 13 411 
In patients with severe AP and IAP > 15 mmHg EN should be initiated via 412 
nasojejunal route starting at 20 mL/hour, increasing the rate according to the 413 
tolerance. Temporary reduction or discontinuation of EN should be considered 414 
when IAP values further increase under EN. 415 
Grade of Recommendation B – Strong consensus (94% agreement) 416 
 417 
Recommendation 14 418 
In patients with severe AP and IAP > 20 mmHg or in the presence of ACS, EN 419 
should be (temporarily) stopped and PN should be initiated. 420 
Grade of Recommendation GPP – Strong consensus (94% agreement) 421 
 422 
Recommendation 15 423 
In patients with severe AP and open abdomen EN should be administered, at least 424 
in a small amount. If required for achievement of nutritional requirements, 425 
supplementary or total PN should be added. 426 
Grade of Recommendation B – Strong consensus (97% agreement) 427 
 428 
Commentary 429 
The mortality of patients with severe AP who develop IAH/ACS during the course of the 430 
disease rises from 25% up to 66% (68, 69). Energy expenditure in patients with AP is 431 
increased by 1.49 (1.08 to 1.78) × the predicted resting energy expenditure; 58% of 432 
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patients with severe AP have an increase in energy expenditure, approximate net 433 
nitrogen loses are 20-40 grams per day, and proteolysis can be increased by 80% (70, 434 
71). There are no data available regarding energy requirements in patients with both AP 435 
and IAH/ACS, however, energy expenditure in such patients may be increased due to 436 
several reasons (decreased splanchnic blood flow, acidosis and bacterial translocation) 437 
(17, 72). 438 
It has been clearly demonstrated that EN in patients with severe AP reduces mortality 439 
and infectious complications, decreases organ failure and surgical intervention rate, has 440 
a trend towards reduction of hospital stay, and is safer and more effective than PN (17). 441 
Nevertheless, it has been reported that EN may increase intraluminal pressure with 442 
subsequent elevation of IAP and development of severe complications (73, 74). 443 
Therefore, it is recommended that EN should be administered with caution when IAP 444 
reaches 15 mmHg and over (74). In an observational study, 274 patients with AP had 445 
IAH and 103 developed ACS. The intolerance of EN was more frequent in patients with 446 
grade III and IV IAH (n=105) and 62/105 (59%) required PN (75). In only one RCT 447 
including 60 patients, comparing early with delayed EN in patients with IAH and severe 448 
AP, it was found that early EN had benefits in patients with IAP < 15 mmHg preventing 449 
development of IAH. In patients with IAP above 15 mmHg abdominal distension was 450 
more frequent in the early EN group. The group of patients with early EN experienced 451 
feeding intolerance more often than patients in delayed EN group. However, early EN 452 
did not increase IAP and was able to ameliorate clinical course of the disease (76). 453 
Because the majority of patients with IAH have gastrointestinal symptoms and signs 454 
(absence of bowel movements, abdominal distension, high gastric residual volume, etc.), 455 
EN should be initiated via nasojejunal tube (77). From a practical point of view, in 456 
patients with severe AP and IAH the initiation of EN should be at 20 mL/hour, increasing 457 
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the rate according to the tolerance. The reduction of EN from higher rates to 20 mL/h 458 
should be considered when IAP increases between 15 and 20 mmHg. In patients with 459 
IAP above 20 mmHg or in the presence of ACS, EN should be (temporarily) stopped (74). 460 
When it is impossible to meet nutritional goals with EN only, supplementary or total PN 461 
should be considered. 462 
A decompressive laparotomy (laparostomy) may be necessary in up to 74% of patients 463 
who develop ACS during course of AP (72). Patients with an open abdomen are in a 464 
hyper-catabolic state with high nitrogen losses and negative nitrogen balance. It has 465 
been estimated that such patients have nitrogen loss of almost 2 g/L of abdominal fluid 466 
output and, therefore, nutritional therapy in patients with an open abdomen is essential 467 
(78). Several cohort studies reported that initiation and feeding by EN was feasible and 468 
safe despite a relatively high rate of digestive intolerance, ranging from 48-67% (78-83). 469 
Two studies concluded that that early EN in patients with an open abdomen resulted in 470 
higher fascial closure rates, lower fistula rates, reduced nosocomial infections and lower 471 
hospital costs (82, 83). In the multicenter analysis by Burlew et al., out of 597 with an 472 
open abdomen patients, EN was successfully initiated in 39% (81). For the 307 patients 473 
without a bowel injury, logistic regression indicated that EN was associated with higher 474 
fascial closure rates (OR 5.3; p <0.01) decreased complication rates (OR, 0.46; p = 0.02), 475 
and decreased mortality (OR 0.30; p = 0.01) (81). 476 
 477 
10. Is there any role for immunonutrition (glutamine, antioxidants) in severe AP? 478 
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Recommendation 16 479 
When EN is not feasible or contraindicated and PN is indicated, parenteral 480 
glutamine should be supplemented at 0.20 g/kg per day of L-glutamine. Otherwise, 481 
there is no role for immunonutrition in severe AP. 482 
Grade of Recommendation B – Strong consensus (94% agreement) 483 
 484 
Commentary 485 
An initial meta-analysis including eleven RCTs assessed the effect of antioxidants (five 486 
RCTs on glutamine and six on various other antioxidants) on the outcome of patients 487 
with AP (84). Among patients with AP, antioxidant therapy resulted in a borderline 488 
significant reduction in hospital stay (mean difference 1.74; 95% CI 3.56 to 0.08), a 489 
significant decrease in complications (RR 0.66; 95% CI 0.46 to 0.95) and a non-490 
significant decrease in mortality rate (RR 0.66; 95% CI 0.30 to 1.46). Nevertheless, these 491 
results were mostly attributed to the effect of glutamine. Recently, a Cochrane Review 492 
assessed the effects of different pharmacological interventions including antioxidants in 493 
patients with AP (85). Very low-quality evidence suggested that none of the 494 
pharmacological treatments decreased short-term mortality in patients with AP.  495 
Regarding glutamine, four meta-analyses have been published. A meta-analysis of ten 496 
RCTs including 433 patients with severe AP revealed a significant decrease in the 497 
incidence of infectious complications and mortality in the patient group with glutamine-498 
enriched nutrition (86). Another meta-analysis of twelve RCTs (including 505 patients) 499 
demonstrated a significantly reduced infection rate and mortality after glutamine 500 
supplementation in patients with AP (87). In the subgroup analyses, only patients who 501 
received total PN demonstrated a significant benefit in terms of study outcomes. Two 502 
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recently published meta-analyses showed beneficial effects of glutamine 503 
supplementation in patients with AP in the terms of elevation of serum albumin 504 
concentrations, decrease in serum concentrations of C-reactive protein, and reductions 505 
in infectious complications, mortality and hospital stay (84, 88). Nevertheless, the risk of 506 
bias of the included studies is important due to many reasons: (i) small sample size in 507 
most of the studies, (ii) possible heterogeneity in disease severity and (iii) confounding 508 
factors such as other interventions that may change outcome (drainage, debridement or 509 
surgery). 510 
 511 
11. Is there any role for probiotic use in severe AP? 512 
Recommendation 17 513 
Probiotics cannot be recommended in patients with severe AP. 514 
Grade of Recommendation 0 – Consensus (89% agreement) 515 
 516 
Commentary 517 
A meta-analysis of six RCTs including 536 patients revealed no significant benefit of 518 
probiotics on pancreatic infection rate, overall infection rate, operation rate, length of 519 
hospital stay and mortality (89). Significant heterogeneity was observed in the type, 520 
dose and treatment duration of probiotics in these trials. In one of these RCTs the 521 
patient group assigned to a particular combination of probiotic strains showed similar 522 
pancreatic infection rate but increased mortality when compared with the placebo 523 
group (90). 524 
 525 
12. Is there any role for the use of oral enzyme supplementation in AP? 526 
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Recommendation 18 527 
Pancreatic enzymes should not be supplemented generally except in patients with 528 
obvious pancreatic exocrine insufficiency (PEI). 529 
Grade of Recommendation B – Strong consensus (97% agreement) 530 
 531 
Commentary 532 
There are only two RCTs with a total of 78 patients randomized to pancreatic enzyme 533 
supplementation or placebo (91, 92). In the study by Kahl et al. 20 of the 56 patients 534 
showed low fecal elastase values indicating PEI. Although the pancreatic enzyme 535 
supplement group showed a tendency for better outcome this did not reach statistical 536 
significance (91). In the second small study by Patankar et al. there was also no 537 
significant difference in laboratory or clinical outcomes (92). Therefore, no conclusion 538 
can be drawn, but enzyme supplementation should be considered in patients with 539 
proven or obvious exocrine insufficiency and malabsorption with steatorrhea. 540 
  541 
26 
 
II. Chronic pancreatitis 542 
 543 
13. What are the risks of developing malnutrition in patients with CP? 544 
Statement 2 545 
Risk of malnutrition in CP is high and malnutrition is common in patients with CP. 546 
Strong consensus (100% agreement) 547 
 548 
Commentary 549 
CP is a disease with progressive and irreversible inflammatory changes in the pancreas 550 
that result in permanent structural damage with fibrosis, which can lead to abdominal 551 
pain and to impairment of exocrine (pancreatic insufficiency) and often endocrine 552 
function (4, 93-95). 553 
Malnutrition is often a late, but important manifestation in the course of CP and depends 554 
on the intensity and duration of the underlying disease. There are differences in the 555 
onset of pancreatic insufficiency and malnutrition between patients with alcoholic and 556 
idiopathic CP. The latency between onset of first symptoms and signs of CP, including 557 
pain and malabsorption/malnutrition is between five to ten years in alcoholic, but 558 
delayed in non-alcoholic pancreatitis (94). 559 
Despite the inconsistency of the data there is an evident risk of malnutrition in patients 560 
with CP (95-97). According to a recent study medium or higher risk for malnutrition 561 
based on Malnutrition Universal Screening Tool (MUST) score of one or higher was 562 
found in 31.5% patients (98). Similarly, 26% underweight patients with a nutritional 563 
risk were identified in a study of outpatients with CP (99).  564 
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At the same time a recent prospective cohort study on 62 patients with CP and 66 565 
controls showed that over half of the patients with CP were overweight or obese (100). 566 
Nevertheless, significant differences in handgrip strength were shown in patients with 567 
CP when compared with controls.  568 
In patients with CP with moderate to severe weight loss, decreased lean body mass and 569 
sarcopenia may lead to decreased functional capacity, which may have an impact on 570 
quality of life (101, 102). In addition, PEI leads to the increased risk of developing 571 
significant bone loss and severe osteoporosis (103, 104). A recent prospective study 572 
(102) including 182 patients with CP showed that sarcopenia was present in 17% (74% 573 
of patients with CP had a BMI > 18.5 kg/m2). During follow-up, sarcopenia was 574 
associated with an increased risk of hospitalization (OR 2.2; 95% CI 0.9 to 5.0; p = 0.07), 575 
increased number of in-hospital days (p < 0.001), and reduced survival (HR 6.7; 95% CI 576 
1.8 to 25.0; p = 0.005).  577 
 578 
14.  What are the causes of malnutrition in patients with CP? 579 
Statement 3 580 
Pancreatic insufficiency, abdominal pain, alcohol abuse, lower food intake, 581 
diabetes mellitus and smoking are the main causes of malnutrition in CP. 582 
Strong consensus (97% agreement) 583 
 584 
Commentary 585 
Multiple risk factors for developing nutrient deficiencies and malnutrition co-exist in 586 
patients with CP. First of all, pancreatic insufficiency (exocrine but also often endocrine) 587 
can lead to maldigestion and malabsorption. Clinical signs of PEI include steatorrhea, 588 
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abdominal pain, weight loss and malnutrition (4). Recent data showed endocrine 589 
insufficiency and/or clinical steatorrhea in 41% and 36% of 809 patients (93). Moreover, 590 
increased resting energy expenditure can be seen in up to 50% of patients with CP, thus 591 
leading to a negative energy balance and malnutrition (105). Furthermore, abdominal 592 
pain, which is frequent in patients with CP, can lead to suboptimal dietary intake and 593 
also contribute to malnutrition (4). 594 
Tobacco is an independent risk factor for CP, and can also be a disease modifier, acting 595 
in synergy with alcohol intake, and therefore, adds to the nutritional risk factors (93). 596 
 597 
15. Which diagnostic tests are preferred to assess nutritional status in patients with CP? 598 
Recommendation 19 599 
Nutritional status should be assessed according to symptoms, organic functions, 600 
anthropometry, and biochemical values. Solely BMI should not be used, because it 601 
does not register sarcopenia in the obese patient with CP. 602 
Grade of Recommendation GPP – Strong consensus (97% agreement) 603 
 604 
Commentary 605 
Studies assessing malnutrition have identified many biochemical factors that are 606 
associated with malnutrition (106, 107) and prevalence studies show a diverse 607 
presentation of malnutrition. Olesen et al. identified that 26% of patients with CP were 608 
underweight in a cross-sectional study of 166 patients with CP (99), whereas Duggan et 609 
al. highlighted that over half of the patients in their prospective controlled cohort study 610 
(n = 128) fell into the overweight/obese category using BMI (100). However, patients 611 
had lower muscle stores and reduced functional status assessed using hand-grip 612 
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strength than healthy controls. Consequently, BMI alone is not considered an adequate 613 
method of assessing nutritional status. Percentage weight loss is considered a more 614 
reliable indicator of the onset of malnutrition and is associated with an increased risk in 615 
the surgical setting (108). 616 
Consequently, nutritional assessment should allow for detection of simple malnutrition, 617 
sarcopenia and micronutrient deficiencies in addition to identifying symptoms that may 618 
predispose patients to worsening malnutrition (Error! Reference source not found.5).  619 
 620 
16. What is the frequency of screening for micro- and macro-nutrient deficiencies in 621 
patients with CP? 622 
Recommendation 20 623 
Patients should undergo screening for micro- and macronutrient deficiencies at 624 
least every twelve months; screening may need to occur more frequently in those 625 
with severe disease or uncontrolled malabsorption. 626 
Grade of Recommendation GPP – Strong consensus (100% agreement) 627 
 628 
Commentary 629 
Patients with CP are at high risk of malnutrition, both in terms of body weight and 630 
altered body composition (100). This has an impact on quality of life (99) and survival 631 
after surgery (109, 110). Nutritional intervention can improve nutritional markers and 632 
is associated with reduced pain (111) and, therefore, routine screening to trigger 633 
nutritional intervention should be undertaken. Deficiencies in micronutrients (vitamin 634 
B12, folic acid, vitamin A, D and E, zinc, selenium, iron) are well documented in patients 635 
with exocrine insufficiency, these are diverse in presentation with some studies 636 
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reporting biochemical deficiencies (100, 103, 112) and case reports document clinical 637 
manifestations including night blindness (113, 114). However, there are no data 638 
recommending the frequency of assessment or the likely timing of progression to 639 
micronutrient deficiency. As clinical manifestation of deficiency represents a late 640 
presentation, routine screening should be implemented to detect early signs of 641 
deficiency.  642 
 643 
17. What recommendations regarding diet and intake of fat, carbohydrates and proteins 644 
should be given in patients with CP? 645 
Statement 4 646 
Patients with CP do not need to follow a restrictive diet. 647 
Strong consensus (94% agreement) 648 
 649 
Recommendation 21 650 
CP patients with a normal nutritional status should adhere to a well-balanced diet. 651 
Grade of Recommendation GPP – Strong consensus (94% agreement) 652 
 653 
Recommendation 22 654 
Malnourished patients with CP should be advised to consume high protein, high-655 
energy food in five to six small meals per day. 656 




Recommendation 23 659 
In patients with CP, diets very high in fiber should be avoided. 660 
Grade of Recommendation B – Strong consensus (91% agreement) 661 
 662 
Statement 5 663 
In patients with CP, there is no need for dietary fat restriction unless symptoms of 664 
steatorrhea cannot be controlled. 665 
Strong consensus (100% agreement) 666 
 667 
Commentary 668 
There are very little data to suggest the optimal dietary management for patients with 669 
CP. Historically, patients were encouraged to have a low-fat diet, and studies in the 670 
Netherlands suggest 48-58% of patients still restrict dietary fat (104, 115). International 671 
guidelines are consistent in their recommendation that patients should have a balanced 672 
diet and avoid fat restriction (4, 116-119). 673 
The role of dietary fat has been examined in small studies, suggesting an improvement 674 
in dyspeptic symptoms in patients with very mild pancreatic disease who did not 675 
consume alcohol regularly when a very low fat diet was consumed (< 20 g fat per day) 676 
(120) and patients who consumed a higher fat diet were thought to be diagnosed at a 677 
younger age, and had an increased probability of continuous abdominal pain (121) 678 
suggesting a potential role in the initial development of CP. However once CP was 679 
diagnosed, there was no difference in severity or complications of disease. An RCT 680 
comparing dietary counselling and nutritional supplements in a cohort of 60 681 
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malnourished patients with CP found that nutritional intervention in which 33% of 682 
energy was derived from fat was well tolerated (111). Improvements in nutritional 683 
status and pain control were observed in patients receiving nutritional intervention and 684 
the authors did not report any adverse events (111). 685 
Patients consuming very high fiber diets reported increased flatulence, and increased 686 
fecal weight and fat losses were observed in a small trial (n = 12) in patients with CP. 687 
This study suggested that very high fiber diets may inhibit pancreatic enzyme 688 
replacement therapy, thus resulting in malabsorption. Thus, very high fiber diets are not 689 
recommended in this patient group (122).  690 
 691 
18. Are oral supplements, with or without medium-chain triglycerides (MCTs), indicated in 692 
patients with CP? 693 
Recommendation 24 694 
Oral nutritional supplements (ONS) should be prescribed to undernourished 695 
patients only if oral nutrition is insufficient for reaching the calorie and protein 696 
goals. 697 
Grade of Recommendation GPP – Strong consensus (100% agreement) 698 
 699 
Recommendation 25 700 
If adequate enzyme supplementation and exclusion of bacterial overgrowth has 701 
not led to relief of malabsorption and its accompanying symptoms, ONS with MCT 702 
can be administered. 703 





Very few studies have investigated the benefit of ONS in patients with CP. Eighty percent 707 
of patients can be treated with diet and enzyme supplementation, the rest need oral 708 
supplementation (96). 709 
ONS can be of benefit in undernourished patients with CP, especially if the caloric and 710 
protein goals cannot be reached with normal meals and counselling. ONS are a simple 711 
way to improve oral intake, but long-term compliance may be a problem. 712 
There are no RCTs investigating the relative efficacy of different formulae (e.g. standard 713 
or peptide-based with MCT). However, in the presence of PEI, enteral formulae 714 
consisting of pre-digested products and a mixture of long chain fatty acids and MCT 715 
would seem, theoretically, to have potential advantage. MCTs are less dependent on 716 
lipase activity for their absorption (123).  717 
A reduction in oral fat intake or the replacement of dietary fat with MCT risks a 718 
reduction in energy intake and, therefore, a negative energy balance. MCTs have an 719 
unpleasant taste and are associated with adverse effects like cramps, nausea, and 720 
diarrhea. Up to now, studies have not shown any clear benefit of MCTs over standard 721 
long-chain triglycerides when used in combination with enzyme supplementation (123, 722 
124). One RCT investigated the efficacy of ONS in patients with CP and severe 723 
malnutrition (111). Dietary counselling achieved equal results compared with the use of 724 
a commercial supplement enriched with MCTs. Both groups also received enzyme 725 
supplementation and so it is not possible to explain the additional gain from dietary 726 
MCTs over enzyme supplementation. 727 
If MCTs are being considered, their dose should be increased slowly depending on the 728 




19. When is micronutrient supplementation indicated in patients with CP (not including 731 
osteoporosis prevention)? 732 
Recommendation 26 733 
Fat-soluble (A, D, E, K) and water-soluble (vitamin B12, folic acid, thiamine) 734 
vitamins as well as minerals such as magnesium, iron, selenium and zinc should 735 
be monitored (if available) and administered if low concentrations are detected 736 
or if clinical signs of deficiency occur. Supplementation should be proposed to 737 
patients with known malabsorption. 738 
Grade of Recommendation GPP – Strong consensus (95% agreement) 739 
 740 
Commentary 741 
The reported prevalence of deficiency of fat-soluble vitamins is 3–14.5% for vitamin A 742 
deficiency (100, 103, 125), 58–77.9% for vitamin D deficiency (100, 103, 125, 126), 9-743 
24% for vitamin E deficiency (100, 103, 106, 125, 126) and 13–63% for vitamin K 744 
deficiency (100, 103, 125, 126). In a prospective controlled cohort study of 128 subjects 745 
and 66 age/gender-matched controls, 14.5% and 24.2% were deficient in vitamins A 746 
and E, respectively, with a significant difference compared with controls. Nineteen 747 
percent of patients had excess serum vitamin A concentrations (100). This must be 748 
taken in account and a blind supplementation of all fat-soluble vitamins for all patients 749 
with CPs is not advised.  750 
Deficiencies of water-soluble vitamins in patients with CP are less frequent. A recent 751 
study with 301 patients with CP and 266 controls showed that patients with CP had 752 
significantly lower concentrations of vitamins A, D and E, but no difference regarding 753 
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vitamin B12 (103). Similarly, another cohort study of 114 patients with CP (33% with 754 
exocrine failure) did not show any significant deficiencies of vitamin B12 (0%) and folic 755 
acid (2.2%) (127).  756 
Thiamine deficiency secondary to concomitant alcoholism must be considered (106). 757 
Minerals and trace elements deficiencies have been reported in patients with CP in some 758 
case-control studies. The results are conflicting. Lower concentrations of zinc, selenium 759 
(106) and magnesium (127) have been observed. Furthermore, low magnesium 760 
concentrations seemed to correlate with exocrine failure (127). 761 
 762 
20. When is EN indicated in patients with CP and how should it be administered? 763 
Recommendation 27 764 
EN should be administered in patients with malnutrition who are not responding 765 
to oral nutritional support. 766 
Grade of Recommendation GPP – Strong consensus (100% agreement) 767 
 768 
Recommendation 28 769 
EN should be administered via the nasojejunal route in patients with pain, delayed 770 
gastric emptying, persistent nausea or vomiting and gastric outlet syndrome. 771 




Recommendation 29 774 
Long-term jejunostomy access (percutaneous endoscopic gastrostomy with 775 
jejunal extension (PEG-J) or direct percutaneous endoscopic jejunostomy (DPEJ) 776 
or surgical jejunostomy) can be used in those requiring EN for more than 30 days.  777 
Grade of Recommendation GPP – Strong consensus (97% agreement) 778 
 779 
Recommendation 30 780 
Semi-elemental formulae with medium chain triglycerides can be used if standard 781 
formulae are not tolerated. 782 
Grade of Recommendation GPP – Strong consensus (94% agreement) 783 
 784 
Recommendation 31 785 
Pancreatic enzymes should be supplemented in patients requiring EN, if signs of 786 
exocrine failure manifest.  787 
Grade of Recommendation GPP – Strong consensus (100% agreement) 788 
 789 
Commentary 790 
Oral nutritional support with dietary counselling is usually sufficient to improve 791 
nutritional status in patients with CP (111). EN is indicated in approximately 5% of 792 
patients with CP (97). Regarding indications and outcomes of EN in these patients, 793 
evidence is based on few cohort studies and RCTs are generally lacking (4). 794 
Four retrospective series have shown the benefits of EN in patients with CP regarding 795 
weight gain and pain control (128-131). Two of them included 58 (129) and 50 patients 796 
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(131) respectively, in whom a naso-jejunal tube was placed. Long-term access with PEG-797 
J or DPEJ was used in 57 (128) and 58 patients (130). All studies showed that this type 798 
of nutritional support was safe and effective in patients with CP, even in case of gastric 799 
outlet syndrome (130, 131). 800 
There is limited high quality evidence for the composition of enteral formulae in 801 
patients with CP. However, there is a rationale that semi-elemental enteral formulae 802 
with MCTs are more adapted for jejunal nutrition, compared with polymeric formulae 803 
(132). In two of the aforementioned studies (129, 131), semi-elemental formulae were 804 
used with good digestive tolerance. Nevertheless, the cost of these feeds is higher and 805 
data on cost-effectiveness are also lacking.  806 
In patients with exocrine failure, who do not improve with semi-elemental formulae, 807 
pancreatic enzymes can be administered with the formula (133). This involves opening 808 
the capsules and suspending the enzyme microspheres in thickened acidic fluid (such as 809 
the mildly thickened or "nectar-thick" fruit juice used for dysphagia) for delivery via the 810 
feeding tube. 811 
 812 
21. When is PN indicated in patients with CP and how should it be administered? 813 
Recommendation 32 814 
PN may be indicated in patients with gastric outlet obstruction and in those with 815 
complex fistulating disease, or in case of intolerance of EN. 816 




Recommendation 33 819 
For PN the preferable route is central venous access. 820 
Grade of Recommendation GPP – Strong consensus (100% agreement) 821 
 822 
Commentary 823 
PN is infrequently uses in patients with CP (4, 97). EN preserves immune function and 824 
mucosal architecture and decreases the possibility for hyperglycemia while PN also 825 
increases the risk of catheter-related infections and septic complications (96, 119). PN 826 
is, therefore, only indicated when it is impossible to use EN (e.g. presence of gastric 827 
outlet obstruction, the need for gastric decompression, when it is impossible to 828 
introduce a tube into the jejunum, or a complicated fistula is present) or if requirements 829 
are only partly reached by EN. PN is mainly administered over a short-term period and 830 
long-term studies are lacking. In this case, a standard nutritional solution should be 831 
administered via central venous access such as a peripherally inserted central catheter. 832 
Contraindications to PN do not differ from general contraindications to medical 833 
nutrition. 834 
 835 
22. What are the indicators for starting pancreatic enzyme replacement therapy (PERT) in 836 
patients with CP? 837 
Recommendation 34 838 
When PEI is diagnosed through clinical signs and symptoms and/or laboratory 839 
tests of malabsorption, PERT shall be initiated. An accurate nutritional 840 
assessment is mandatory to detect signs of malabsorption. 841 
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Grade of Recommendation A – Strong consensus (100% agreement) 842 
 843 
Commentary 844 
PEI is defined as an insufficient secretion of pancreatic enzymes (acinar function) 845 
and/or sodium bicarbonate (ductal function) (4). Diagnosis of PEI can be challenging in 846 
practice because pancreatic function and secretion are not solely reliant on the quantity 847 
or quality of pancreatic tissue (134) but also depend on complex pancreatic stimulatory 848 
mechanisms (135). Moreover, different PEI biomarkers and their threshold values have 849 
been used in the current literature (136). For these reasons a wide range (from 22% to 850 
94%) of prevalence rates for PEI among patients with CP has been reported (98, 106, 851 
137-146).  852 
The most frequent clinical sign of PEI is steatorrhea (147), defined as presence of fat in 853 
the stool, and associated generally with flatulence, bloating, dyspepsia, urgency to pass 854 
stools, and cramping abdominal pain. In a recent systematic review, including 14 studies 855 
on pancreatic enzyme supplementation in patients with CP, the criteria for the diagnosis 856 
of PEI were the measurement of the coefficient of fat absorption with a threshold < 80% 857 
or the fecal fat absorption less than 7 - 15 g of fat per day (136). 858 
Overt steatorrhea is not expected unless there is severe or decompensated PEI (i.e. 859 
when secretion of pancreatic lipase is less than < 10% of normal). However, the absence 860 
of overt steatorrhea is not always an indicator of adequate absorption and nutritional 861 
status. PEI is consistently associated with biochemical and clinical signs of malnutrition 862 
(148). Management of PEI involves replacing the inadequate pancreatic enzymes, which 863 
should be used to maintain weight and improve the symptoms of maldigestion (149). 864 
Awareness of PEI among many physicians is poor outside of referral centers and 865 
especially among physicians in primary care (115). Consequentially, patients who 866 
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present with symptoms of PEI may be overlooked or advised to adopt inappropriate 867 
dietary restrictions in an attempt to control the symptoms. A study identified that the 868 
primary unmet patient need was the difficulty in managing gastrointestinal symptoms, 869 
diet, and digestion; indeed, many of these patients and caregivers cited delays in dietary 870 
assessment and initiation of PERT causing additional distress that could have been 871 
prevented (150). Untreated PEI has also a deleterious impact on the quality of life of 872 
patients (151). As the quantitative measurement of fecal fat is often omitted, it is 873 
recommended that enzyme replacement is started when clinical signs of malabsorption, 874 
or anthropometric and/or biochemical signs of malnutrition are present (96, 127, 152-875 
154). Symptoms include weight loss, alteration of body compartments at bioimpedance 876 
analysis, and low nutritional markers (albumin, cholinesterase, prealbumin, retinol-877 
binding protein, and magnesium) (127). Although it is assumed that steatorrhea is the 878 
most important clinical manifestation of PEI, several studies have shown reduced 879 
absorption of fat-soluble vitamins even in patients with mild to moderate PEI (155-158). 880 
Non-alcoholic fatty liver disease (NAFLD) is also a poorly recognized complication of 881 
PEI. The mechanisms underlying NAFLD in PEI is different from NAFLD associated with 882 
metabolic syndrome, because it is mainly due to malabsorption of essential amino acids 883 
such as choline which leads to a decrease in plasma concentrations of apoprotein B 884 
(159), a major component of very-low-density lipoprotein. 885 
 886 
23. What are the enzyme preparations of choice for PERT? 887 
Recommendation 35 888 
pH-sensitive, enteric-coated microspheres pancreatic enzyme replacement 889 
preparations shall be used for treating PEI. 890 
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Grade of Recommendation A – Strong consensus (100% agreement) 891 
 892 
Commentary 893 
There are multiple pancreatic enzyme replacement preparations that are now licensed 894 
around the world. All are of porcine origin and contain, with varying concentrations and 895 
mixtures, pancreatic lipase, amylase, protease, and other pancreas-derived proteins and 896 
nucleic acids. Several factors affect the efficacy of pancreatic enzyme supplementation: 897 
(a) mixture with meal; (b) gastric emptying with meal; (c) mixing with chyme and bile 898 
acids and rapid release of enzymes in duodenum (160).  899 
Nowadays, most of the pancreatic enzyme preparations are formulated as pH-sensitive, 900 
enteric-coated, capsules containing microspheres or tablets that protect the enzymes 901 
from gastric acidity and allow them to disintegrate rapidly at pH > 5.5 in the duodenum 902 
(160, 161). Non enteric-coated, conventional powder or tablet formulations have been 903 
abandoned because they are less effective in treating PEI as pancreatic enzymes are 904 
partially inactivated by pepsin and gastric acidity (162). 905 
The efficacy of these more recent formulations has been demonstrated in several recent 906 
studies (163-166) and in a recent meta-analysis (136). A Cochrane review on the 907 
efficacy of pancreatic enzyme preparations in patients with pancreatic insufficiency 908 
demonstrated a higher efficacy for enteric-coated microspheres compared with enteric-909 
coated tablets (167). Mini-microspheres 1.0 - 1.2 mm in diameter seem to be associated 910 
with higher therapeutic efficacy compared with 1.8 - 2.0 mm microspheres that still 911 
have an optimal therapeutic action (168). Another trial compared two enteric-coated 912 
pancreatic enzyme preparations. One moisture-resistant, formulated to contain between 913 
90% to 110% labeled lipase content over the shelf life of the product and the other 914 
potentially unstable in the presence of moisture and degradable over time. The 915 
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characteristics of the moisture-resistant formulation should have allowed more accurate 916 
dosing, both providing more predictable therapeutic effects and reducing the risk of 917 
overdose, which is assumed as a potential risk factor for fibrosing colonopathy. The 918 
results suggested a comparable efficacy and safety in patients with cystic fibrosis for the 919 
treatment of PEI (169). 920 
 921 
24. How should enzyme supplementation be administered? 922 
Recommendation 36 923 
Oral pancreatic enzymes should be distributed along with meals and snacks.  924 
Grade of Recommendation B – Strong consensus (100% agreement) 925 
 926 
Commentary 927 
The efficacy of pancreatic enzyme supplements presupposes the mixing of enzymes and 928 
chyme (161). While one study evaluating the impact of the scheduling of PERT 929 
administration on fat malabsorption suggested the optimal timing of administration was 930 
during or after meals, no significant difference was observed when patients took PERT 931 
immediately before meals (170). In practice, although many patients prefer to take 932 
PERT at the beginning of meals, they should be encouraged to spread the capsules out 933 
over a meal when using multiple capsules or with larger meals (162, 170). If the patient 934 
is taking the older preparations of pancreas powder, they should take about a third of 935 
the dose immediately before, one third during, and one third immediately after the meal. 936 
This concerns only meals and snacks that contain fat (e.g. not for fruit).  937 
 938 
25. What is the optimal dosage of enzyme supplementation? 939 
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Recommendation 37 940 
The posology aims at individual needs and depends on the severity of the disease 941 
and the composition of the meal. In practice, a minimum lipase dose of 20,000 - 942 
50,000 PhU (based on the preparation) shall be taken together with main meals, 943 
and half that dose with snacks.  944 
Grade of Recommendation A – Strong consensus (100% agreement) 945 
 946 
Commentary 947 
The dosage recommended depends on the patient’s clinical response, but the dosage and 948 
dosing will need to be monitored carefully, as well as altered, depending on patient’s 949 
food intake/pattern of eating, method of cooking, portion sizes, and disease evolution.  950 
For the digestion of a normal meal a minimum activity of 30,000 IU of naturally secreted 951 
pancreatic lipase is required. The recommended initial dose is about 10% of the 952 
physiologically secreted dose of lipase after a normal meal (171). Since 1 IU of naturally 953 
secreted lipase equals 3 PhU in commercial preparations, the minimum amount of lipase 954 
needed for digestion of a normal meal is 90,000 PhU (endogenous plus orally 955 
administered lipase). 956 
The results of several RCTs have proven the efficacy of pancreatic enzyme replacement 957 
therapy with enteric-coated mini-microspheres at a dose ranging from 40,000 - 80,000 958 
PhU of lipase per main meal, and half dose per snack (165, 166, 170, 172-174). Studies 959 
evaluating enteric-coated microspheres have shown a similar efficacy for doses ranging 960 
from 10,000 - 40,000 PhU of lipase per meal, indicating the lack of a dose-response 961 
relationship with these preparations (175, 176). 962 
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Dose escalation may be warranted according to response. In adults there is no upper 963 
limit to dosing, as there is no risk of overdose because pancreatic enzymes exceeding the 964 
needs are eliminated through stools. Caution for dosage should be placed in children in 965 
whom colonic strictures have been described after high dose of the enteric coated, 966 
delayed release preparations (177). 967 
 968 
26. How should the efficacy of enzyme supplementation be evaluated? 969 
Recommendation 38 970 
The efficacy of PERT should be evaluated by the relief of gastrointestinal 971 
symptoms and the improvement of nutritional parameters (anthropometric and 972 
biochemical). In patients who do not respond, the evaluation should be extended 973 
to pancreatic function tests (fecal fat excretion or 13C-MTG-breath test).  974 
Grade of Recommendation B – Strong consensus (97% agreement) 975 
 976 
Commentary 977 
The aforementioned recent meta-analysis including 14 RCTs (136) showed that PERT 978 
increased the coefficient of fat absorption, as well as improved gastrointestinal 979 
symptoms, compared with baseline or placebo. Two open label extensions up to one 980 
year from RCTs included in the meta-analysis demonstrated significant improvement in 981 
nutritional parameters and weight (164, 178). A review of reported data (106) as well as 982 
the recent guidelines on the therapy for CP (4) support the use of nutritional parameters 983 
as an optimal way to assess the efficacy of PERT. Dietary intake and nutritional status 984 
should be monitored regularly to maximize patient compliance and specialist dietetic 985 
assessment sought in patients with underlying malnutrition (179). 986 
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In patients who do not respond, pancreatic function tests (136) while on PERT can 987 
monitor effectiveness. 13C-MTG-breath test is a useful method that can replace the 988 
somewhat cumbersome fecal fat excretion tests and can be used for patients on PERT 989 
(180). 990 
 991 
27. What should be done in cases of unsatisfactory clinical response? 992 
Recommendation 39 993 
In case of unsatisfactory clinical response, PERT dosage should be increased or a 994 
protein pump inhibitor (PPI) should be added. If these methods fail, other causes 995 
of malabsorption such as small intestinal bacterial overgrowth (SIBO) should be 996 
excluded. 997 
Grade of Recommendation B – Strong consensus (97% agreement) 998 
 999 
Commentary 1000 
The recommended dose of 20,000 - 50,000 PhU with main meals has been shown to 1001 
improve symptoms in more than half the patients (136). Dose escalation may be 1002 
warranted according to response. In adults there is no upper limit to dosing, as there is 1003 
no risk of overdose because pancreatic enzymes exceeding the needs are eliminated in 1004 
the stool. Caution for high PERT dosage should be exercised in children, in whom colonic 1005 
strictures have been described after high dose of the enteric coated, delayed release 1006 
preparations (177). 1007 
The inhibition of gastric acid secretion by PPIs can lead to a significant improvement 1008 
and even normalization of fat digestion in patients with an incomplete response to 1009 
PERT, as shown in a prospective cohort study of 21 patients with CP (43% had an initial 1010 
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incomplete response to PERT, and 29% normalized their function after addition of a 1011 
PPI) (181). Nevertheless, a review including 34 clinical trials failed to show 1012 
improvement in the efficacy of PERT with PPI or histamine-2 receptor antagonists 1013 
(182). It is noteworthy that the populations included and the therapeutic schemes were 1014 
very heterogeneous, therefore, suggesting significant bias.  1015 
SIBO can also explain persistent symptoms. A recent prospective case-control study 1016 
revealed that SIBO was present in 15% of patients with CP whereas no healthy control 1017 
was tested positive by means of a fasting glucose hydrogen breath test (183).  1018 
 1019 
28. Does the surgical technique for treating CP affect PERT and nutritional status? 1020 
Recommendation 40 1021 
Long-term PERT and nutritional status are similarly affected by all surgical 1022 
procedures. Tissue-preserving procedures shall be preferred. 1023 
Grade of Recommendation A – Strong consensus (100% agreement) 1024 
 1025 
Commentary 1026 
Surgical intervention is effective in carefully selected patients. Common indications for 1027 
surgical intervention in CP include poorly controlled pain, duodenal, biliary and 1028 
pancreatic duct obstruction, and suspicion of cancer (184).  1029 
Surgery for CP can be broadly classified into three categories: drainage procedures, 1030 
partial pancreatic resection including or not the duodenum, and total pancreatectomy. 1031 
Recently, Kamper et al. (185), reviewed all the available techniques in detail. In drainage 1032 
procedures a dilated pancreatic duct is cut open and anastomosed to the proximal 1033 
jejunum. The most common drainage procedures are the modified Puestow procedure, 1034 
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also known as lateral pancreatico-jejunostomy, and the Frey procedure, which in 1035 
addition to a pancreaticojejunostomy includes coring of the pancreatic head. In patients 1036 
with persistent inflammation of the pancreatic head without upstream ductal dilatation, 1037 
a resective surgery such as a classic pancreaticoduodenectomy or a duodenum-1038 
preserving head resection (Beger procedure) can be performed.  1039 
Theoretically, the type of procedure may deeply affect short- and long-term nutritional 1040 
outcomes, since the extension of the parenchyma resection, as well as the preservation 1041 
of the duodenum and bile natural transit, and pancreatic secretion may represent key 1042 
factors for endocrine and exocrine functions (186, 187).  1043 
Meta-analyses showed better postoperative pain relief and improved quality of life with 1044 
the Beger procedure compared with conventional pancreaticoduodenectomy (188, 189). 1045 
However, the studies included had a high grade of heterogeneity and a recent large 1046 
prospective large RCT showed no significant difference between procedures in the long-1047 
term nutritional status, quality of life, and preservation of the exocrine pancreatic 1048 
function (190).  1049 
A 2015 meta-analysis of 23 studies compared outcomes of the Frey procedure with 1050 
pancreaticoduodenectomy and the Berger procedure (191). Short-term quality of life 1051 
and pancreatic function outcomes were more favorable in patients who had the Frey 1052 
procedure than in those who had pancreaticoduodenectomy. Long-term follow-up data 1053 
from an RCT comparing the Frey and Berger procedures for CP showed no significant 1054 
difference in endocrine or exocrine insufficiency more than a decade after surgery 1055 
(192). 1056 
 1057 
29. What is the risk of developing osteoporosis or osteopenia in patients with CP? 1058 
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Statement 6 1059 
Patients with CP are at risk for osteoporosis (almost one out of four) and at high 1060 
risk (about two out of three), for osteopathy (either osteoporosis or osteopenia). 1061 
Strong consensus (97% agreement) 1062 
 1063 
Commentary 1064 
Osteoporosis is characterized by structural deterioration of bone tissue and low bone 1065 
mass, leading to bone fragility and increased risk of fracture (193). Osteoporosis and 1066 
osteopenia are defined by the World Health Organization according to T-scores (a T-1067 
score between –1.0 and –2.5 standard deviations is defined as osteopenia; a T-score 1068 
below 2.5 standard deviations is defined as osteoporosis), T-scores compare bone 1069 
density values with those of young adults (peak bone mass) (194). Osteoporosis and 1070 
osteopenia can also be defined according to Z-score (Z-score < –1 defined as osteopenia, 1071 
Z-score < –2 defined as osteoporosis). The Z-scores represents gender- and age-matched 1072 
controls for the evaluation of secondary osteoporosis, they are usually used in 1073 
premenopausal women, men under the age of 50, and in children (195). 1074 
A systematic review and meta-analysis including ten studies applied the definition in 1075 
accordance with the T-scores in eight and the Z-scores in two studies. It revealed that, 1076 
based on the random-effects model of the total 513 patients with CP included, a pooled 1077 
prevalence rate of osteoporosis of 24.3% (95% CI 16.6 to 32.0%) and osteopathy (either 1078 
osteoporosis or osteopenia) of 65% (95% CI 54.7 to 74.0%) (196). Two of the included 1079 
studies revealed osteoporosis rate for controls respectively 8.6 and 10.2%. All the 1080 
included studies had relatively small sample sizes (< 100) and considerable 1081 
heterogeneity; therefore, subgroup analyses were not acquiescent. Certain patterns 1082 
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were, however, evident from the studies included, like an association between 1083 
pancreatic enzyme insufficiency and lower bone mineral density. On the contrary, the 1084 
available data failed to show direct associations between serum vitamin D 1085 
concentrations and low bone mineral density. These data suggest that vitamin D 1086 
deficiency is not the sole driver of bone demineralization, other factors that may be of 1087 
importance for premature bone demineralization in CP are heavy smoking, low physical 1088 
activity, and chronic inflammation (197).  1089 
The important clinical endpoint of osteoporosis is bone fracture. Two large 1090 
retrospective studies shed light on this regarding patients with CP. The first is a cohort 1091 
database study, examining patients with CP at a single tertiary care center. A total of 1092 
3,192 patients with CP and 1,436,699 controls were included in the study. The fracture 1093 
prevalence (patients with fracture per total patients) was 1.1% in controls 1094 
(16,208/1,436,699) and 4.8% in patients with CP (154/3192); in comparison Crohn’s 1095 
disease revealed a risk of 3.0% (182/6057); liver cirrhosis 4.8% (805/16,658) and 1096 
celiac disease 5.0% (74/1480) (198). 1097 
The second, a Danish retrospective cohort study including 2594 patients with CP 1098 
revealed an adjusted hazard ratio for any fracture of 1.7 (95% CI 1.6 to 1.8) (199). 1099 
Patients with CP receiving PERT for fat malabsorption had a lower risk of fractures than 1100 
other CP patients (HR 0.8; 95% CI 0.7 to 0.9). 1101 
 1102 
30. What methods should be used to identify patients who are at risk? 1103 
Recommendation 41 1104 
Dual-energy X-ray absorptiometry (DXA) shall be used to identify patients with CP 1105 
with osteopathy. 1106 
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Grade of Recommendation A – Strong consensus (100% agreement) 1107 
 1108 
Commentary 1109 
The American College of Radiology aims to rate the appropriateness of several 1110 
radiological modalities for specific patient populations. Although they do not mention CP 1111 
explicitly, they do state that in premenopausal females and males 20 - 50 years of age 1112 
with malabsorption, DXA of the lumbar spine and hip(s) or distal forearm is usually an 1113 
appropriate diagnostic modality to identify low bone mineral density (200). It is not yet 1114 
well defined when and to whom these tests should be offered in patients with CP. 1115 
However, there are recommendations from the American Gastroenterological 1116 
Association on the detection of osteoporosis in other gastrointestinal diseases: 1117 
recommending that patients with at least one additional osteoporosis risk factor should 1118 
undergo initial screening with DXA (201). This recommendation was specifically for 1119 
inflammatory bowel disease, celiac disease, and post-gastrectomy patients. The recently 1120 
published HaPanEU guidelines on CP argued that bone density testing by DXA should be 1121 
extended to patients with CP with an additional risk; post-menopausal women, those 1122 
with previous low-trauma fractures, men over 50 years and those with malabsorption 1123 
(4). They further stated that considering the associated morbidity and cost of bone 1124 
fractures when prevention is within range (202), a baseline bone density assessment for 1125 
all patients with CP may be worth considering. 1126 
 1127 




Recommendation 42 1130 
Basic preventive measures should be advised to all patients with CP including 1131 
adequate calcium/vitamin D intake and, if indicated, pancreatic enzyme 1132 
supplementation, regular weight-bearing exercise and smoking and alcohol 1133 
avoidance. Additional pharmacologic treatment should be reserved for patients 1134 
with osteopathy and, in particular, osteoporosis. 1135 
Grade of Recommendation GPP – Strong consensus (97% agreement) 1136 
 1137 
Commentary 1138 
The reasons for osteopathy in CP are multifactorial; (i) low serum vitamin D 1139 
concentrations due to impaired absorption of fat-soluble vitamin D, poor dietary intake 1140 
(including calcium) and/or sunshine exposure, (ii) smoking and alcohol intake, (iii) low 1141 
physical activity, and (iv) chronic inflammation, all contribute. Therefore, basic 1142 
preventive measures should be advised to all patients with CP including adequate 1143 
calcium/vitamin D intake and PERT if indicated, regular weight-bearing exercise and 1144 
avoidance of smoking and alcohol (4). Research on pharmaceutical supplementation of 1145 
vitamin D and calcium in patients with osteopenia and adding bisphosphonates in 1146 
osteoporosis has mainly been performed in post-menopausal women and elderly 1147 
patients. Based on these findings, and bearing in mind that the cost and side effects are 1148 
limited, one could consider in patients with osteopathy to supplement vitamin D (800 1149 
IU) and calcium (500 - 1,000 mg) daily (149). In patients with osteopenia it is 1150 
recommended to repeat the DXA every two years, whereby in patients with osteoporosis 1151 
there are no specific recommendations beside appropriate medication, screening for 1152 
other causes and/or referral to a bone specialist (4). 1153 
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Figure legends 1180 
Figure 1: Algorithm suggesting nutritional management in acute pancreatitis. HTG: 1181 
hypertriglyceridemia; EN: enteral nutrition; PN: parenteral nutrition. Adapted from 1182 
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Table 1. Levels of evidence 
1++  High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 
1+  Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 
1-  Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++  High quality systematic reviews of case control or cohort studies. High quality case control or 
cohort studies with a very low risk of confounding or bias and a high probability that the 
relationship is causal 
2+  Well-conducted case control or cohort studies with a low risk of confounding or bias and a 
moderate probability that the relationship is causal 
2-  Case control or cohort studies with a high risk of confounding or bias and a significant risk that 
the relationship is not causal 
3  Non-analytic studies, e.g. case reports, case series 
4  Expert opinion 
According to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Source: SIGN 50: A guideline developer’s 
handbook. Quick reference guide October 2014 [SIGN 50]. RCT=randomized controlled trial 
 
Table 2. Grades of recommendation (6) 
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to 
the target population; or  
A body of evidence consisting principally of studies rated as 1+, directly applicable to the target 
population, and demonstrating overall consistency of results 
B A body of evidence including studies rated as 2++, directly applicable to the target population; 
or 
A body of evidence including studies rated as 2+, directly applicable to the target population 
and demonstrating overall consistency of results; or 
Extrapolated evidence from studies rated as 1++ or 1+ 
0 Evidence level 3 or 4; or 
Extrapolated evidence from studies rated as 2++ or 2+ 
GPP Good practice points/expert consensus: Recommended best practice based on the clinical 
experience of the guideline development group 










Table 3. Classification of the strength of consensus 
Strong consensus Agreement of >90% of the participants 
Consensus Agreement of >75-90% of the participants 
Majority agreement Agreement of 50-75 % of the participants 
No consensus Agreement of <50% of the participants 
According to the AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Association of the Scientific 
Medical Societies in Germany) methodology (8) 
 
 
Table 4. Criteria for systematic search for literature – databases, filters and 
keywords  
Publication date From 1977 to December 2018 
Language English 
Databases Pubmed, EMBASE, Cochrane library 
Filters human 
Publication type Cohort study, controlled trial, systematic review 
Keywords Acute pancreatitis, chronic pancreatitis, nutrition 
 
 









• Change in body weight 
• Functional assessment: 
Hand-grip strength 
dynamometry / 6-
minute walk tests / sit 
to stand tests. 
• Skin fold thickness, 
waist circumference 
and mid arm muscle 
circumference.  
• Presence of ascites / 
edema 
 
• Fat soluble vitamins (A, 
D, E, K) 
• Bone health 
(Parathyroid hormone)  
• Trace elements 
(magnesium, selenium, 
zinc) 
• Anemia screen (iron 
studies, B12, folate, 
ferritin and CRP) 
• Glycemic control: 
HbA1c and random 
glucose 
• Change in dietary 
intake 
• Appetite 
• Presence of 
symptoms that impact 
on oral intake (nausea 
/ pain / indigestion / 
early satiety) 
• Presence of exocrine / 
endocrine 
dysfunction 
• CT / US imaging of 
muscle stores 
(muscle mass) 
• DXA scanning (bone 
mineral density) 
CRP = C-reactive protein, HbA1c = hemoglobin A1c, CT = computed tomography, US = ultrasound, DXA = dual-energy X-ray 
absorptiometry 
 

